Urmen Desai, MD, learned at an early age the rewards of caring for others. His parents ran several nursing homes in the Boston area. “When I was young, I would go to work with my mother and father. I would chat and play games with the patients,” he says. “As I got a older, my after-school job was working as an activities counselor in one of the nursing homes—playing bingo and organizing card games.”...
Urmen Desai, MD, learned at an early age the rewards of caring for others. His parents...
Giving and receiving gifts is a normal occurrence in most people’s personal and...
When healthcare attorney Bradford E. Adatto, Esq. of Dallas-based firm ByrdAdatto...
Many aesthetic practices and medspas have already embraced video as an effective...
Canfield Scientific’s VECTRA H2 offers an all-in-one portable lightweight 3D...
Topix Pharmaceuticals' Replenix Pure Hydration Plumping Lip Treatment Broad...
Capture consistent before-and-after images with FotoFinder’s new Automated...
Epionce Renewal Calming Cream from Episciences soothes sensitive, eczema-...
 Revance Therapeutics has released SAKURA Phase 3 study data for its injectable daxibotulinumtoxinA (RT002) for moderate-to-severe glabellar lines. The study included nearly 2,700 patients, who received up to three treatments and were followed for more than a year and a half. Based on...
|
 New grants are now available from the National Rosacea Society (NRS) to support research into potential causes and other key aspects of rosacea that may lead to improvements in its management, prevention or potential cure.
“The NRS research grants program has been a leading force for many...
|
Revance Therapeutics has released SAKURA Phase 3 study data for its injectable daxibotulinumtoxinA (RT002) for moderate-to-severe glabellar lines. The study included nearly 2,700 patients, who received up to three treatments and were followed for more than a year and a half. Based on investigator assessment, more than 95 percent of patients achieved a score of none or mild glabellar lines at maximum frown at week 4 after each of three treatments. The median time to return to baseline was 28 weeks. The median time to loss of none or mild wrinkle severity was 24 weeks. These results were consistent with those seen in the Phase 3 pivotal trials, SAKURA 1 and SAKURA 2.
“The results of this trial are exceptional since they demonstrate that RT002 has consistently and predictably produced long duration and high response rates and was well tolerated over successive treatments,” said SAKURA investigator Jean Carruthers, MD.
At week 1, 95.8 percent of patients had none or mild wrinkles. This increased to 97.7 percent after the third treatment. The most common treatment-related adverse events were headache (3.3 percent of treatments), injection site pain (2.7 percent) and injection site erythema (2.5 percent). There were...
New grants are now available from the National Rosacea Society (NRS) to support research into potential causes and other key aspects of rosacea that may lead to improvements in its management, prevention or potential cure.
“The NRS research grants program has been a leading force for many years in advancing the understanding of the disease process of rosacea,” said Richard Gallo, MD, chairman of dermatology at the University of California, San Diego, and a member of the NRS Medical Advisory Board. “We are now looking forward to increasing this knowledge still further through the support of new studies that may lead to important improvements in patient care and the development of new therapeutic options.”
Funded by donations from rosacea sufferers, the NRS research grants program has awarded more than $1.5 million to support 70 studies, including scientific investigations that have connected the dots in the inflammatory process of the disorder. Other studies have investigated the genetics of rosacea, the skin’s microbiome, changes to tear film development in ocular rosacea, and many other areas.
Because the etiology of rosacea is unknown, high priority will be given to studies relating to such areas as...
Merz Americas, a division of Merz Aesthetics, has launched a new consumer-facing advertising campaign for Xeomin (incobotulinumtoxinA) called “Later Haters,” which calls for women to “X out” judgment, stop apologizing for caring about how they look and put an end to feeling guilty about their self-care routines.
Merz’ marketing team brought together groups of girlfriends to learn more about their views on beauty. In the course of these conversations, the women revealed that they wanted to embrace their self-confidence and make choices about looking and feeling their best without guilt or judgment. The company named this group, “The Reclaimers,” describing them as women who have spent the last several years building a career or raising a family, taking care of everyone and everything else, who are finally saying, “it’s time to get back to me.” They are the target group of the new campaign.
“Traditionally, external judgment has held women back from seeking injections or, if they do, from talking about it, for fear of being labeled as someone who is fake and self-absorbed. Xeomin’s ‘Later Haters’ campaign takes on a new tone, embracing today’s woman and her right to live her life on her terms, without judgment,”...
The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.
The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.
The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »
Merz Aesthetics has begun commercial shipment of the Cellfina System, indicated for long-term improvement in the appearance of cellulite in the buttocks and thighs, to aesthetic practices in the U.S.
Cellfina combines proprietary technology with minimally invasive subcision to treat the primary structural cause of dimpled cellulite. Results of the procedure last at least two years—in clinical trials, patient satisfaction with their treatment results improved from 94% at one year to 96% at the two-year mark. The most common side effects reported were soreness, tenderness and bruising... more »
